Key result
Single-pill amlodipine/atorvastatin reduces both blood pressure and cholesterol and may help improve the management of patients with concomitant hypertension and dyslipidaemia.
Why the study?
Does single-pill amlodipine/atorvastatin improve the management of patients with concomitant hypertension and dyslipidaemia?
Does single-pill amlodipine/atorvastatin improve the management of patients with concomitant hypertension and dyslipidaemia?
Single-pill amlodipine/atorvastatin offers a combined approach to simultaneously lower blood pressure and cholesterol in patients with both hypertension and dyslipidaemia.
May support single-pill use in comorbid hypertension and dyslipidaemia; leaves open need for outcome trials.
Single-pill amlodipine besylate/atorvastatin calcium (Caduet), Pfizer Inc, NY, USA) is the first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia (DYS). The benefits of lowering blood pressure (BP) in patients with HTN and lowering cholesterol in patients with DYS are well known and well studied. However, worldwide, many patients with HTN have concomitant DYS, which places them at greater risk for cardiovascular disease compared with patients with just one of these risk factors. Clinical trials have demonstrated that amlodipine plus atorvastatin can be safely co-administered across the dose range. Single-pill amlodipine/atorvastatin reduces both BP and cholesterol and may help to improve the management of patients with concomitant HTN and DYS.
No takes yet. Share an insight, caveat, or question.
Martín Cowie (2005) conducted a review in Hypertension and dyslipidaemia. Single-pill amlodipine/atorvastatin was evaluated. Single-pill amlodipine/atorvastatin reduces both blood pressure and cholesterol and may help improve the management of patients with concomitant hypertension and dyslipidaemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: